Skip to main content


Risk Factors for Rheumatoid Arthritis-associated Interstitial Lung Disease

Sparks and colleagues have published a matched cohort analysis demonstrating risk factors that may augment the risk of rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), especially the combination of obesity, high CRP, high MD-HAQ and >30 pack-year smoking history. 

NSAID Safety with COVID-19 Infection

NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.

Insurers Bet Big on Bribing Patients

Madelaine Feldman, MD, and Jay Salliotte

Last month, psoriasis patients covered by Cigna received a curious letter from the insurance giant's pharmacy management division. They could receive a $500 debit card from Cigna, with just one string attached: they would have to switch to a different medication, one preferred by the insurer.

AURORA-1: Voclosporin Efficacy in Lupus Nephritis

Lancet has published the results of the AURORA-1 trial, wherein the calcineurin inhibitor, voclosporin, was tested in a placebo controlled trial of lupus nephritis and shown to be effective at inducing a complete renal response.

FDA Advisors Split on Avacopan for Vasculitis

MedPage Today

Members of an FDA advisory panel were sharply divided as to whether avacopan, an oral small molecule inhibitor of the C5a receptor, was sufficiently safe and effective for treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Higher Hydroxychloroquine Blood Levels Reduces Thrombosis Risk in Lupus

Petri and colleagues have published that measuring hydroxychloroquine (HCQ) blood levels can be useful in systemic lupus erythematosus (SLE), as low levels are associated with an increased thrombotic risk in SLE.

Avacopan for ANCA Vasculitis Goes in Front of the FDA

MedPage Today

An FDA advisory panel will consider whether to recommend approval of an oral C5a inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, with agency staff raising questions over the "clinical meaningfulness" of key study data.

RheumNow Podcast – Falling or Falling in Love?

Dr. Jack Cush reviews the best journal articles from the past week on

Unique Oral Microbiome in Early and Pre-Clinical RA

An oral microbiome study of rheumatoid arthritis patients suggests that periodontal condition in patients with early rheumatoid arthritis and individuals at risk of RA.

ARTIC REWIND - Don't Half DMARD Therapy

The ARTIC-REWIND study examined rheumatoid arthritis (RA) patients in remission on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to see if they could "step-down" their csDMARDs theray; but  the study showed that 25% those who went on half-dose experienced disease flares

Drug Monitoring Ineffective with Infliximab Treatment

The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not.

Childhood Lupus May Hamper Adult Careers

Long-term outcomes of kids with childhood-onset systemic lupus erythematosus (cSLE) are uncommon, but this cSLE cohort analysis suggests that SLE significantly impacts their future education, vocation, and employment as they reach adulthood.